Which non-carbapenem antibiotics are active against extended-spectrum ß-lactamase-producing Enterobacteriaceae?
Int J Antimicrob Agents
; 52(1): 100-103, 2018 Jul.
Article
in En
| MEDLINE
| ID: mdl-29580930
ABSTRACT
In this study, the activity of 18 non-carbapenem antibiotics was evaluated against 100 extended-spectrum ß-lactamase (ESBL)-producing Escherichia coli (ESBL-Ec) and 50 ESBL-producing Klebsiella pneumoniae (ESBL-Kp) isolated from urinary tract infections and bacteraemia in 2016. Minimum inhibitory concentrations (MICs) were determined using reference methods and the susceptibility profiles were defined according to European Committee on Antimicrobial Susceptibility Testing (EUCAST) 2017 recommendations. All of the ESBL-Ec isolates were susceptible to ceftazidime/avibactam and a great majority of them were susceptible to fosfomycin (98%), piperacillin/tazobactam (97%), amikacin (97%) and nitrofurantoin (96%). Mecillinam, cefoxitin and ceftolozane/tazobactam remained active against 92%, 83% and 78% of the ESBL-Ec isolates, respectively. Moreover, 100%, 94% and 90% of the ESBL-Kp tested were susceptible to ceftazidime/avibactam, amikacin and mecillinam, respectively. This study showed that there are non-carbapenem options (including orally administrable drugs) for the treatment of all of the situations of ESBL-Ec or ESBL-Kp infections, with ceftazidime/avibactam being the most efficient alternative.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Beta-Lactamases
/
Enterobacteriaceae
/
Anti-Bacterial Agents
Type of study:
Guideline
Limits:
Humans
Language:
En
Journal:
Int J Antimicrob Agents
Year:
2018
Document type:
Article
Affiliation country: